{
    "id": 1752,
    "name": "ocular melanoma",
    "source": "DOID",
    "definition": "An ocular cancer that has_material_basis_in melanocytes and is located_in the eye. [url:http\\://www.cancer.gov/dictionary?CdrID=269467]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1752",
    "evidence": [
        {
            "id": 10644,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",
            "molecularProfile": {
                "id": 27655,
                "profileName": "GNAQ Q209L PTEN R173S"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1752,
                "name": "ocular melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1066,
                    "pubMedId": 23434733,
                    "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01252251",
            "title": "RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2261,
                    "therapyName": "Everolimus + Pasireotide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01801358",
            "title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 1114,
                    "therapyName": "AEB071 + Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03528408",
            "title": "Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042506",
            "title": "SBRT as a Vaccination for Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}